Figure 1

A

ALT (U/L)

month of immunisation

NOD control
NOD CYP2D6/FTCD
HLA-DR3 control
HLA-DR3 CYP2D6/FTCD

B

serum titer ANA

serum titer anti-LKM1/LC1

D

weight of liver (g)

E

LMNCs count (X10^6) /g liver tissue
Figure 2

Panel A: 
- NOD
- HLA-DR3

Panel B: 
- NOD
- HLA-DR3

CONTROL
CYP2D6/FTCD

Figure 2
Figure 2
**Figure 4**

A. Control vs. CYP2D6/FTCD for IL4+ in CD4+ cells (%):
- **Control**: IL4, SSC-A subset CD4 15.5%
- **CYP2D6/FTCD**: IL4, SSC-A subset CD4 9.6%

B. Bar graph showing significantly increased IL4+ in CD4+ cells (%):
- **Control**:
- **CYP2D6/FTCD**:

C. Control vs. CYP2D6/FTCD for IL17A+ in CD4+ cells %:
- **Control**: IL17, SSC-A subset CD4 6.09%
- **CYP2D6/FTCD**: IL17, SSC-A subset CD4 10.7%

D. Bar graph showing significantly increased IL17A+ in CD4+ cells %:
- **Control**:
- **CYP2D6/FTCD**:

E. Control vs. CYP2D6/FTCD for IFN-γ+ in CD8+ cells (%):
- **Control**: IFNγ, SSC-A subset CD8 23.3%
- **CYP2D6/FTCD**: IFNγ, SSC-A subset CD8 97.4%

F. Bar graph showing significantly increased IFN-γ+ in CD8+ cells %:
- **Control**:
- **CYP2D6/FTCD**:

G. Control vs. CYP2D6/FTCD for TNF-α+ in CD8+ cells (%):
- **Control**: TNFa, SSC-A subset CD8 30.6%
- **CYP2D6/FTCD**: TNFa, SSC-A subset CD8 66.2%

H. Bar graph showing significantly increased TNF-α+ in CD8+ cells %:
- **Control**:
- **CYP2D6/FTCD**:

**Legend:**
- **IL4**: Interleukin 4
- **IL17A**: Interleukin 17A
- **IFN-γ**: Interferon-gamma
- **TNF-α**: Tumor necrosis factor alpha
- **SSC**: Side scatter
Figure 5

A

stimulation index

concentration of CYP2D6/FTCD DNA

B

stimulation index

LMNCs

NOD HLA-DR3

C

stimulation index

spleenocytes

NOD HLA-DR3

D

stimulation index

dilution

E

stimulation index

dilution

N.S.
Figure 6

Graphs showing the levels of IgA, IgM, IgG2a, IgG2b, IgG1, and IgA after treatment with control or CYP2D6/FTCD. The x-axis represents the sample groups, and the y-axis represents the concentration in ng/ml. The control group is represented in black, and the CYP2D6/FTCD group is represented in gray. The graphs indicate that there are no significant differences (ns) in IgA, IgM, IgG2a, IgG2b, and IgG1 levels between the control and treatment groups. However, there is a significant difference (*) in IgG1 levels between the control and treatment groups.
Figure 7

A

B

C

% relative bacteria sequence (phylum)

% relative bacteria sequence (genus)
Supplementary Figure 1

A

NOD

HLA-DR3

CYP2D6/FTCD

B

α-SMA

LOX

LOXL2

TGF-β

relative expression

NOD control
NOD CYP2D6/FTCD
HLA-DR3 control
HLA-DR3 CYP2D6/FTCD

relative expression

NOD control
NOD CYP2D6/FTCD
HLA-DR3 control
HLA-DR3 CYP2D6/FTCD

relative expression

NOD control
NOD CYP2D6/FTCD
HLA-DR3 control
HLA-DR3 CYP2D6/FTCD

relative expression

NOD control
NOD CYP2D6/FTCD
HLA-DR3 control
HLA-DR3 CYP2D6/FTCD